Monalisa Soft — Hy-BRID HA Filler for Fine Wrinkles & Tear Trough (200µm)

Monalisa Soft is GENOSS’s lightest variant — 24 mg/mL cross-linked HA + 0.3% lidocaine with the smallest particle size (200µm) in the Monalisa range. Engineered via patented Hy-BRID technology for superficial dermal placement targeting tear trough, fine periorbital wrinkles, and delicate skin zones. BDDE residue <2 ppm (manufacturer-tested undetectable).

Monalisa Soft with Lidocaine is manufactured by GENOSS Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2007. The product is part of the Monalisa dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE 2195 · KGMP · ISO 13485 · ISO 9001.

Monalisa Soft with Lidocaine contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using GENOSS Co. Ltd.’s Hy-BRID Cross-Linking Technology (200µm particles) technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per GENOSS Co. Ltd.’s clinical data, Monalisa Soft with Lidocaine delivers Up to 6 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Superficial dermis placement typically delivers the longer end of the duration range.

Monalisa Soft with Lidocaine is engineered for superficial dermis placement. The standard recommended needle is 30G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Monalisa Soft with Lidocaine regulatory status: KFDA registered · CE 2195 · KGMP · ISO 13485 · ISO 9001. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Monalisa Soft with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Monalisa Soft with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Monalisa Soft with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Monalisa Soft uses 200µm HA particles — the smallest in the GENOSS Monalisa range and significantly smaller than typical mid/high-density fillers. The small particle size combined with the Hy-BRID monophasic structure allows the gel to integrate smoothly into the thin tear trough skin without visible lumps or the Tyndall effect (blue discolouration) that can occur with larger-particle fillers in this zone. The 30G needle and conservative dosing protocol further support safe periorbital placement.